Deposition of Inhaled Prolastin in Cystic Fibrosis Patients
Status:
Completed
Trial end date:
2004-06-01
Target enrollment:
Participant gender:
Summary
The objective of this trial is to determine the optimal region of the lung for depositing
Prolastin (alpha-1 antitrypsin; AAT) by inhalation in order to treat cystic fibrosis (CF).
The AKITA® nebulizer has settings which can be varied to target the inhaled drug to either
the deep lung or to the upper airways in a one to one randomization. The study will measure
how much of the activity of the enzyme elastase is inhibited by AAT.
Phase:
Phase 2
Details
Lead Sponsor:
Grifols Therapeutics Inc. Grifols Therapeutics LLC